ArticleScientific reports2026
Unveiling key pathways and potential biomarkers for high-altitude hypertension: a pilot multi-omics study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
High altitude has a considerable impact on the pathophysiology of the human cardiovascular system and disease occurrence. We aim to use an integrated approach of metabolomics and proteomics to reveal key pathways and biomarkers of hypertension at high altitude. Thirty Tibetan patients with hypertension and 30 healthy individuals residing on the Tibetan Plateau at a very high altitude (> 4500 m) were included in the study. Metabolomic analysis was conducted using Vanquish ultra-high performance liquid chromatography, while proteomic analysis utilized the timsTOF Pro2 mass spectrometer. Correlation analysis revealed key signaling pathways and biomarkers associated with hypertension in Tibetan patients. The results showed 87 differentially expressed metabolites and 61 differentially expressed proteins in individuals with hypertension at high altitude. The results of metabolomic differential metabolite pathway analysis indicated that Caffeine metabolism had the most significant impact. Specific metabolites like PI(16:0/16:0), Caffeine, and Plastoquinone 3 were found to be significantly up-regulated in hypertensive patients. The combination of five metabolites achieved an area under the curve (AUC) of 0.871 for hypertension prediction. Proteomic analysis revealed that the identified differential proteins primarily functioned in signaling receptor binding. It was confirmed that Creatine kinase B (CKB) and Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta (YWHAZ) could serve as a protein biomarker combination for hypertension in plateau regions, showing an AUC of 0.764 (0.585-0.944). Upon conducting an integrated analysis of metabolomics and proteomics, the combined AUC improved to 0.982 (0.949-1.000). A comprehensive analysis utilizing metabolomics and proteomics revealed that alterations in signal transduction-related pathways and lipid metabolism pathways were implicated in hypertension among plateau populations. Additionally, YWHAZ was observed as a potential biomarker for this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.